Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2022
Sentynl agrees to acquire Nulibry rights
Zydus Lifesciences said its US subsidiary Sentynl Therapeutics entered an agreement to acquire global rights to BridgeBio Pharma's Nulibry asset. Sentynl will lead ongoing development and US commercialization, while BridgeBio will share development responsibilities through specified regulatory approvals.
2021
Zydus reduces Remdac price to Rs 899
Zydus reduced the price of its Remdac brand of Remdesivir to Rs 899 for a 100 mg lyophilized injection, from Rs 2,800 at launch.
2020
Zydus launches Remdac in India
Zydus announced that it launched Remdesivir under the Remdac brand in India. The product was priced at Rs. 2,800 per 100 mg lyophilized injection and was to be distributed through the group's network to government and private hospitals treating COVID-19 patients.
2019
Medicure acquires Zypitamag ownership for the U.S. and Canadian markets
Medicure announced that, through its subsidiary Medicure International Inc., it had acquired ownership of Zypitamag from Zydus for the U.S. and Canadian markets. The agreement provides for upfront and deferred payments, milestone payments, and royalties related to net sales.